
IL-23 inhibitors linked to lower psoriatic arthritis risk than JAK inhibitors, and IL-17 inhibitors showed higher risk.
Supplements and Featured Publications
Highlights from the American College of Rheumatology Annual Meeting (ACR), which took place on November 11-16, 2016 in Washington, DC.